Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia

被引：56

作者：

Lierman, Els ^{[1
]}

Selleslag, Dominik ^{[2
]}

Smits, Sanne ^{[3
]}

Billiet, Johan ^{[2
]}

Vandenberghe, Peter ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Ctr Human Genet, Univ Hosp Leuven, B-3000 Louvain, Belgium

[2] Acad Hosp St Jan, Brugge, Belgium

[3] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium

来源：

BLOOD | 2012年 / 120卷 / 07期

关键词：

D O I：

10.1182/blood-2012-06-433821

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1529 / 1531

页数：5

共 8 条

[1] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[2] PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms [J].

Hoeller, Sylvia ;

Walz, Christoph ;

Reiter, Andreas ;

Dirnhofer, Stephan ;

Tzankov, Alexandar .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) :53-62

[3] A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia [J].

Lacronique, V ;

Boureux, A ;

DellaValle, V ;

Poirel, H ;

Quang, CT ;

Mauchauffe, M ;

Berthou, C ;

Lessard, M ;

Berger, R ;

Ghysdael, J ;

Bernard, OA .

SCIENCE, 1997, 278 (5341) :1309-1312

[4] Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia [J].

Peeters, P ;

Raynaud, SD ;

Cools, J ;

Wlodarska, I ;

Grosgeorge, J ;

Philip, P ;

Monpoux, F ;

VanRompaey, L ;

Baens, M ;

VandenBerghe, H ;

Marynen, P .

BLOOD, 1997, 90 (07) :2535-2540

[5] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms [J].

Quintas-Cardama, Alfonso ;

Vaddi, Kris ;

Liu, Phillip ;

Manshouri, Taghi ;

Li, Jun ;

Scherle, Peggy A. ;

Caulder, Eian ;

Wen, Xiaoming ;

Li, Yanlong ;

Waeltz, Paul ;

Rupar, Mark ;

Burn, Timothy ;

Lo, Yvonne ;

Kelley, Jennifer ;

Covington, Maryanne ;

Shepard, Stacey ;

Rodgers, James D. ;

Haley, Patrick ;

Kantarjian, Hagop ;

Fridman, Jordan S. ;

Verstovsek, Srdan .

BLOOD, 2010, 115 (15) :3109-3117

[6] The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 [J].

Reiter, A ;

Walz, C ;

Watmore, A ;

Schoch, C ;

Blau, I ;

Schlegelberger, B ;

Berger, U ;

Telford, N ;

Aruliah, S ;

Yin, JA ;

Vanstraelen, D ;

Barker, HF ;

Taylor, PC ;

O'Driscoll, A ;

Benedetti, F ;

Rudolph, C ;

Kolb, HJ ;

Hochhaus, A ;

Hehlmann, R ;

Chase, A ;

Cross, NCP .

CANCER RESEARCH, 2005, 65 (07) :2662-2667

[7] JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma [J].

Van Roosbroeck, Katrien ;

Cox, Luk ;

Tousseyn, Thomas ;

Lahortiga, Idoya ;

Gielen, Olga ;

Cauwelier, Barbara ;

De Paepe, Pascale ;

Verhoef, Gregor ;

Marynen, Peter ;

Vandenberghe, Peter ;

De Wolf-Peeters, Chris ;

Cools, Jan ;

Wlodarska, Iwona .

BLOOD, 2011, 117 (15) :4056-4064

[8] A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis [J].

Verstovsek, Srdan ;

Mesa, Ruben A. ;

Gotlib, Jason ;

Levy, Richard S. ;

Gupta, Vikas ;

DiPersio, John F. ;

Catalano, John V. ;

Deininger, Michael ;

Miller, Carole ;

Silver, Richard T. ;

Talpaz, Moshe ;

Winton, Elliott F. ;

Harvey, Jimmie H., Jr. ;

Arcasoy, Murat O. ;

Hexner, Elizabeth ;

Lyons, Roger M. ;

Paquette, Ronald ;

Raza, Azra ;

Vaddi, Kris ;

Erickson-Viitanen, Susan ;

Koumenis, Iphigenia L. ;

Sun, William ;

Sandor, Victor ;

Kantarjian, Hagop M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :799-807

← 1 →